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CASE REPORT 
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Treatment of Aortic Thrombosis in a Premature Neonate 
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Department ofPaediatric Surgery, Great Ormond Street Hospital for Children, London WCIN 3JH, U.K. 
Introduction 
Thrombolysis has been used in children and infants 
in the treatment ofatrial thrombosis, aortic thrombosis, 
pulmonary embolism, prosthetic valve and shunt 
thrombosis and renal vein thrombosis. 1 In neonates, 
surgical thrombectomy is technically hazardous in 
large vessels and may be complicated in peripheral 
vessels by endothelial damage, stenosis of vessels and 
also by incomplete clot removal. The best treatment 
for limb- or life-threatening thromboses in neonates i
therefore not well definedF 
We report the use of the second generation throm- 
bolytic agent recombinant issue plasminogen ac- 
tivator (rTPA; Actilyse ® Boehringer Ingelheim) in the 
treatment of an acute aortoiliac thrombosis associated 
with umbilical artery catheterisation i  a premature 
neonate. 
Case Report 
A 31 week gestation female infant weighing 1.25 kg 
underwent intubation and mechanical ventilation at 
24 h for respiratory distress syndrome. An umbilical 
artery catheter (UAC) was inserted, the tip being po- 
sitioned at the level of the 10th thoracic vertebra. The 
UAC had been used for monitoring only and no 
hyperosmolar fluids had been instilled through it. 
Thirty six hours after insertion of the UAC, the right 
leg was cyanosed but femoral pulses were palpable 
and the UAC was removed. Over the succeeding 48 h 
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both legs became increasingly cyanosed and mottled 
and the femoral pulses became impalpable. 
The baby was transferred to this hospital with critical 
ischaemia of both legs. Colour duplex ultrasound scan- 
ning demonstrated aortic thrombosis with bilateral 
femoral artery occlusions. It was decided to treat this 
patient with rTPA systemically via peripheral intra- 
venous infusion according to the regimen shown in 
Table 1. 
There was an initial improvement. After a single 
dose of rTPA both legs became pink, with the exception 
of the right hallux which remained cyanosed. The 
femoral pulses, however, remained impalpable. 
Daily colour duplex scans were used to monitor 
treatment and cranial ultrasound scans used to check 
for bleeding complications. Electrolyte and clotting 
screens were performed aily to monitor enal function 
and any coagulopathy. 
After the first 3 days of lysis aortic thrombosis was 
still present from below the origin of the superior 
mesenteric artery to the femoral arteries (Fig. 1). 
In view of this a further 3 day course of rTPA was 
given. This was successful in clearing the thrombosis 
completely on duplex scan and restoring the femoral 
pulses and viability of the right hallux. 
The baby was given intravenous heparin, monitored 
with an activated partial thromboplastin time at twice 
Table 1. Dose regimen employed. 
1.5 mg/kg rTPA once daily for 3 days. 




10% i.v. stat over 1-2 min 
50% as infusion over I h 
40% as infusion over 2 h 
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Fig. 1. Duplex ultrasound emonstrating thrombus occluding aorta. 
to three times normal, measured twice a day. This was 
continued for a further 3days as an empirical measure 
in order to prevent recurrence of the thrombosis. 
Two days after the final infusion of rTPA she had 
an episode of melaena nd bile stained nasogastric 
aspirates. Necrotising enterocolitis was diagnosed, she 
was treated appropriately with antibiotics and par- 
enteral feeding and her symptoms settled. 
Follow-up of the infant at 5 months showed her to 
have normal symmetrical limb growth, a full com- 
plement of pulses and no neurological deficit. 
Discussion 
Mild asymptomatic to severe aortic thrombosis is a 
recognised complication of UACs, detected by duplex 
scanning in around 26% of cases. 2 Despite this UACs 
are commonly placed in premature infants for the 
purpose of monitoring. Removal of the UAC may be 
sufficient to prevent progression. 1 The question of how 
to treat those that become symptomatic has not been 
settled. A surgical solution in the form of trans- 
abdominal aortotomy and thrombectomy has been 
reported in normal gestation and weight neonates 
but not without mortality and long-term morbidity. 3 
Peripheral ischaemia due to aortic thrombosis has been 
treated with streptokinase or urokinase often with 
mixed results. I'4-6 This is only the third case report of 
the use of rTPA in aortic thrombosis associated with 
a UAC. The functional outcome in the first case was 
associated with the loss of four toes  In their patient 
a shorter course and no heparin was used. The ~econd 
case was more similar to ours but the thrombus was 
less extensive, sparing the renal arteries and requiring 
10 h of rTPA infusion compared with a total of 18 h 
(6 x 3 h infusions) for complete resolution. 8 The mes- 
sage when reviewing the three cases together is that 
thrombolysis should be continued until clot resolution 
is confirmed by duplex ultrasound and not simply on 
clinical grounds. Also there may be value in post- 
thrombolysis heparinisation. 
The interesting factor in this case is the early res- 
olution of symptoms, after the first dose, but the 
persistence of duplex detectable thrombus and absent 
pulses, tn addition with thrombus extending to be- 
neath the superior mesenteric artery gut and renal 
perfusion must have been affected early. It may be 
that the initial dose of rTPA was enough to open up 
collaterals and the melaena fter the treatment finished 
was also a reflection of this. However, renal function 
at no time appeared affected. 
The patient in this report was haemodynamically 
stable throughout; whether this treatment is safe in 
situations of fluctuating blood pressure is not es- 
tablished. A lower dose schedule delivered at the 
thrombus itself might be effective but access may be 
a problem. Obviously where a UAC is in situ then 
thrombolysis may be infused directly into the throm- 
bosis; however, as the UAC is the aetiological factor 
its early removal is indicated. In addition, many will 
wish to avoid arterial puncture for intra-arterial lysis 
when treating complications of such intervention. 
Our experience suggests that rTPA at these doses 
systemically can be used safely and with no significant 
haemorrhagic side effects and should be considered 
when major arterial thrombosis has occurred in neo- 
nates. 
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